Compare INBS & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INBS | CDIO |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.6M |
| IPO Year | N/A | N/A |
| Metric | INBS | CDIO |
|---|---|---|
| Price | $4.21 | $3.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 44.8K | 25.7K |
| Earning Date | 02-12-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,292,042.00 | $15,782.00 |
| Revenue This Year | $778.48 | $1,434.82 |
| Revenue Next Year | N/A | $4,661.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.26 | N/A |
| 52 Week Low | $4.30 | $2.42 |
| 52 Week High | $27.50 | $30.60 |
| Indicator | INBS | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.57 | 45.31 |
| Support Level | $0.54 | $3.24 |
| Resistance Level | $7.25 | $3.53 |
| Average True Range (ATR) | 0.55 | 0.34 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 54.69 | 26.12 |
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.